Janux Therapeutics, Inc. (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell ...

Tattoo ink doesn’t just sit inertly in the skin. New research shows it moves rapidly into the lymphatic system, where it can persist for months, kill immune cells, and even ...

Tattoos might seem like harmless self-expression, but could they secretly raise your skin cancer risk? A new Swedish study ...

A hallmark of cancerous cells is an abnormal number of chromosomes or chromosome arms, known as aneuploidy. While aneuploidy ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of ...

On November 19, 2025, the Food and Drug Administration granted accelerated approval to Bayer’s (BAYRY) sevabertinib, a kinase inhibitor, for ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) ...

Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.

Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, ...

BioAtla (NASDAQ:BCAB) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints for the OSV ...